Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Miscelaneous Frontpage Notices Previous | All Articles This Week | Next
This article originally posted 13 October, 2009 and appeared in  Issue 490

Miscellaneous Front Page #490

FitbitNew Product: FITbit: Tracks Fitness & Sleep Quality

The Fitbit accurately tracks your calories burned, steps taken, distance traveled and sleep quality. The Fitbit tracks your motion in three dimensions and converts this into useful information about your daily activities. You can wear the Fitbit on your waist, in your pocket or on undergarments. At night, you can wear the Fitbit in order to track your sleep. Anytime you walk by the included wireless base station, data from your Fitbit is silently uploaded in the background to Fitbit.com. Cost is $99. www.fitbit.com

 

 

NEW! Tool for Your Practice: Free CE/CME program 

Patient Education: You Can Do IT!

This lecture by Ginger Kanzer-Lewis fills the knowledge gap by teaching health care providers and diabetes educators how and what to teach patients, how to motivate patients, and how to train other health care professionals to teach patients. (40 minutes) Go to this lecture.

 

News Flash: FDA Safety Changes for Sulfonylureas

Use of Sulfonylureas Linked to Hemolytic Anemia in Patients with G6PD Deficiency.G6PD deficiency is an X-linked recessive hereditary condition in which red blood cells break down when the body is exposed to the stress of infection or certain drugs. Clinical manifestations include hemolytic anemia, abdominal and/or back pain, dizziness, headache, dyspnea, and palpitations. FDA U.S. Food & Drug Administration

 

Tolerx Phase 3 Study:

DEFEND is a Phase 3 clinical study of otelixizumab in YOUNG ADULTS with newly diagnosed T1DM. Otelixizumab is an investigational agent, not yet approved by the FDA for marketing. DEFEND will determine if otelixizumab can help preserve the ability to make endogenous insulin and stop the destruction of the body's cells that make insulin (beta cells). You can find out more at www.defendagainstdiabetes.com

 

Career Opportunity:

CDE/Pump Trainer Opportunity
Philadelphia, Baltimore/DC, and Tampa

Medingo has received FDA clearance for the Solo MicroPump Insulin Delivery System and is seeking  experienced diabetes educators with insulin pump training experience to launch the product on the East Coast – especially Philadelphia, Baltimore/DC,  Atlanta and Tampa.   Please send your resume to jobs@medingo.com. Visit us at www.solo4you.com.

 

Advertisement
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 13 October, 2009 and appeared in  Issue 490

Past five issues: Diabetes Clinical Mastery Series Issue 137 | Issue 677 | Diabetes Clinical Mastery Series Issue 136 | Issue 676 | Diabetes Clinical Mastery Series Issue 135 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
What test do you use to screen for prediabetes?

Navigate Diabetes In Control
Search Articles On Diabetes In Control